MedTrace Logo

Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa

NCT01683253 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-03-10

No results posted yet for this study

Summary

The purpose of this study is to see whether the ICDs(Impulse Control Disorder) are improved and neuropsychiatric traits related to ICD are changed or not when switching dopamine agonist to levodopa/carbidopa in patients with Parkinson's disease who have been treated with dopaminergic medications.

Conditions

  • Impulse Control Disorder

Interventions

DRUG

Levodopa/Carbidopa(200mg/50mg)

DRUG

Dopaminergic Agonists

Treated for at least 6 months after diagnosis of Parkinson's Disease.

Sponsors & Collaborators

Principal Investigators

  • Jinwhan Cho, MD · Samsung Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01683253 on ClinicalTrials.gov